Identification and Functional Verification of CITED2 Gene Promoter Region in Patients with Patent Ductus Arteriosus.
Zhuo ChenHuan-Xin ChenHai-Tao HouXiu-Yun YinQin YangGuo-Wei HePublished in: International journal of molecular sciences (2023)
Patent ductus arteriosus (PDA) is a common congenital heart disease. CITED2 plays an important role in the development of the heart, and genetic variants in its coding region are significantly associated with cardiac malformations. However, the role of variants in the promoter region of CITED2 in the development of PDA remains unclear. We extracted the peripheral blood of 646 subjects (including 353 PDA patients and 293 unrelated healthy controls) for sequencing. We identified 13 promoter variants of the CITED2 gene (including 2 novel heterozygous variants). Of the 13 variants, 10 were found only in PDA patients. In mouse cardiomyocytes (HL-1) and rat cardiac myocytes (RCM), the transcriptional activity of the CITED2 gene promoter was significantly changed by the variants ( p < 0.05). The results of the experiments of electrophoretic mobility indicated that these variants may affect the transcription of the CITED2 gene by influencing the binding ability of transcription factors. These results, combined with the JASPAR database analysis, showed that the destruction/production of transcription factor binding sites due to the variants in the promoter region of the CITED2 gene may directly or indirectly affect the binding ability of transcription factors. Our results suggest for the first time that variants at the CITED2 promoter region may cause low expression of CITED2 protein related to the formation of PDA.
Keyphrases
- transcription factor
- copy number
- dna methylation
- genome wide identification
- genome wide
- dna binding
- gene expression
- end stage renal disease
- congenital heart disease
- newly diagnosed
- peripheral blood
- ejection fraction
- chronic kidney disease
- left ventricular
- binding protein
- emergency department
- oxidative stress
- patient reported outcomes
- small molecule
- heat shock
- adverse drug
- data analysis